Abstract
2'-Deoxy-3'-thiacytidine is a dideoxycytidine analog with a sulfur in place of the 3' carbon of the ribose. There are two enantiomeric forms of the compound, both of which inhibit human immunodeficiency virus type 1 and 2 replication in vitro. However, the (-) enantiomer (lamivudine) appears to be significantly less cytotoxic to uninfected lymphocytes than is the (+) enantiomer. Lamivudine has entered initial clinical trials, and the present study was designed to describe the pharmacokinetic behavior of this compound in both plasma and cerebrospinal fluid (CSF) of primates. Lamivudine was administered as an intravenous bolus dose of 20 mg/kg for 24 h for administration. Urine samples were also obtained from two animals. The same dose of the racemate (BCH-189) was administered to one animal. The drug was quantitated in CSF and plasma with a reverse-phase high-pressure liquid chromatography technique. Elimination of lamivudine from plasma was biexponential, with a mean alpha phase half-life of 5.4 min, a mean beta phase half-life of 84 min, and a total clearance of 6.1 liters/h. The total clearance of the same dose of BCH-189 in a single animal was 11.0 liters/h. In two animals from which urine was obtained for 12 h postadministration, 32 and 59% of the drug was recovered unchanged. The deamination product of lamivudine was not detected. The CSF/plasma ratio of lamivudine was significantly higher when the drug was measured in the lumbar CSF (mean, 0.41) than when it was measured in the ventricular CSF (mean, 0.079). The measured CSF/plasma ratio for ventricular CSF is equivalent to that of other dideoxycytidine analogs, confirming the importance of the nucleobase in determining the degree of CSF penetration. The difference in lamivudine exposure in ventricular and lumbar CSF suggests that there is a transport mechanism for efflux of cytidine analogs from ventricular CSF.
Full Text
The Full Text of this article is available as a PDF (184.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blaney S. M., Balis F. M., Hegedus L., Heideman R. L., McCully C., Murphy R. F., Kelley J. A., Poplack D. G. Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res. 1990 Dec 15;50(24):7915–7919. [PubMed] [Google Scholar]
- Coates J. A., Cammack N., Jenkinson H. J., Mutton I. M., Pearson B. A., Storer R., Cameron J. M., Penn C. R. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992 Jan;36(1):202–205. doi: 10.1128/aac.36.1.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Collins J. M., Klecker R. W., Jr, Kelley J. A., Roth J. S., McCully C. L., Balis F. M., Poplack D. G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther. 1988 May;245(2):466–470. [PubMed] [Google Scholar]
- Knott G. D. Mlab--a mathematical modeling tool. Comput Programs Biomed. 1979 Dec;10(3):271–280. doi: 10.1016/0010-468x(79)90075-8. [DOI] [PubMed] [Google Scholar]
- McCully C. L., Balis F. M., Bacher J., Phillips J., Poplack D. G. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci. 1990 Sep;40(5):520–525. [PubMed] [Google Scholar]
- Poplack D. G., Bleyer W. A., Wood J. H., Kostolich M., Savitch J. L., Ommaya A. K. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res. 1977 Jul;37(7 Pt 1):1982–1985. [PubMed] [Google Scholar]
- van Leeuwen R., Lange J. M., Hussey E. K., Donn K. H., Hall S. T., Harker A. J., Jonker P., Danner S. A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992 Dec;6(12):1471–1475. doi: 10.1097/00002030-199212000-00008. [DOI] [PubMed] [Google Scholar]